{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T17:55:41Z","timestamp":1769277341659,"version":"3.49.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2020,12,11]],"date-time":"2020-12-11T00:00:00Z","timestamp":1607644800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,12,11]],"date-time":"2020-12-11T00:00:00Z","timestamp":1607644800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Pharmacol Sin"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1038\/s41401-020-00570-8","type":"journal-article","created":{"date-parts":[[2020,12,11]],"date-time":"2020-12-11T11:20:56Z","timestamp":1607685656000},"page":"1516-1523","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["Anti-PD-L1 mediating tumor-targeted codelivery of liposomal irinotecan\/JQ1 for chemo-immunotherapy"],"prefix":"10.1038","volume":"42","author":[{"given":"Zhi-di","family":"He","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yong-hui","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yang","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hai-rui","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bin-fan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bin","family":"Tu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Si-qi","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yong-zhuo","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,12,11]]},"reference":[{"key":"570_CR1","doi-asserted-by":"publisher","first-page":"3384","DOI":"10.1172\/JCI80011","volume":"125","author":"L Chen","year":"2015","unstructured":"Chen L, Han X. Anti-PD-1\/PD-L1 therapy of human cancer: past, present, and future. J Clin Invest. 2015;125:3384\u201391.","journal-title":"J Clin Invest"},{"key":"570_CR2","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1002\/jcp.27172","volume":"234","author":"FK Dermani","year":"2019","unstructured":"Dermani FK, Samadi P, Rahmani G, Kohlan AK, Najafi R. PD-1\/PD-L1 immune checkpoint: potential target for cancer therapy. J Cell Physiol. 2019;234:1313\u201325.","journal-title":"J Cell Physiol"},{"key":"570_CR3","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.3390\/ijms18061324","volume":"18","author":"A Passardi","year":"2017","unstructured":"Passardi A, Canale M, Valgiusti M, Ulivi P. Immune checkpoints as a target for colorectal cancer treatment. Int J Mol Sci. 2017;18:1324.","journal-title":"Int J Mol Sci"},{"key":"570_CR4","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1093\/annonc\/mdu100","volume":"25","author":"J Goldstein","year":"2014","unstructured":"Goldstein J, Tran B, Ensor J, Gibbs P, Wong HL, Wong SF, et al. Multicenter retrospective analysis of metastatic colorectal cancer (CRC) with high-level microsatellite instability (MSI-H). Ann Oncol. 2014;25:1032\u20138.","journal-title":"Ann Oncol"},{"key":"570_CR5","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.cllc.2017.06.015","volume":"19","author":"S Takamori","year":"2018","unstructured":"Takamori S, Toyokawa G, Takada K, Shoji F, Okamoto T, Maehara Y. Combination therapy of radiotherapy and anti-PD-1\/PD-L1 treatment in non-small-cell lung cancer: a mini-review. Clin Lung Cancer. 2018;19:12\u20136.","journal-title":"Clin Lung Cancer"},{"key":"570_CR6","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.pharmthera.2018.01.003","volume":"186","author":"M Mathew","year":"2018","unstructured":"Mathew M, Enzler T, Shu CA, Rizvi NA. Combining chemotherapy with PD-1 blockade in NSCLC. Pharmacol Ther. 2018;186:130\u20137.","journal-title":"Pharmacol Ther"},{"key":"570_CR7","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1016\/j.apsb.2019.01.018","volume":"9","author":"J Wei","year":"2019","unstructured":"Wei J, Long Y, Guo R, Liu X, Tang X, Rao J, et al. Multifunctional polymeric micelle-based chemo-immunotherapy with immune checkpoint blockade for efficient treatment of orthotopic and metastatic breast cancer. Acta Pharm Sin B. 2019;9:819\u201331.","journal-title":"Acta Pharm Sin B"},{"key":"570_CR8","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","volume":"378","author":"L Gandhi","year":"2018","unstructured":"Gandhi L, Rodriguez-Abreu D, Gadgeel S, Esteban E, Felip E, De Angelis F, et al. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N Engl J Med. 2018;378:2078\u201392.","journal-title":"N Engl J Med"},{"key":"570_CR9","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.ejca.2017.02.003","volume":"76","author":"M Del Rio","year":"2017","unstructured":"Del Rio M, Mollevi C, Bibeau F, Vie N, Selves J, Emile JF, et al. Molecular subtypes of metastatic colorectal cancer are associated with patient response to irinotecan-based therapies. Eur J Cancer. 2017;76:68\u201375.","journal-title":"Eur J Cancer"},{"key":"570_CR10","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1007\/s00262-010-0926-x","volume":"60","author":"TJ Haggerty","year":"2011","unstructured":"Haggerty TJ, Dunn IS, Rose LB, Newton EE, Martin S, Riley JL, et al. Topoisomerase inhibitors modulate expression of melanocytic antigens and enhance T cell recognition of tumor cells. Cancer Immunol Immunother. 2011;60:133\u201344.","journal-title":"Cancer Immunol Immunother"},{"key":"570_CR11","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1093\/jnci\/djx257","volume":"110","author":"JA McKenzie","year":"2018","unstructured":"McKenzie JA, Mbofung RM, Malu S, Zhang M, Ashkin E, Devi S, et al. The effect of topoisomerase I inhibitors on the efficacy of T-cell-based cancer immunotherapy. J Natl Cancer Inst. 2018;110:777\u201386.","journal-title":"J Natl Cancer Inst"},{"key":"570_CR12","doi-asserted-by":"publisher","first-page":"301","DOI":"10.3109\/1547691X.2012.693547","volume":"9","author":"B Frey","year":"2012","unstructured":"Frey B, Stache C, Rubner Y, Werthmoller N, Schulz K, Sieber R, et al. Combined treatment of human colorectal tumor cell lines with chemotherapeutic agents and ionizing irradiation can in vitro induce tumor cell death forms with immunogenic potential. J Immunotoxicol. 2012;9:301\u201313.","journal-title":"J Immunotoxicol"},{"key":"570_CR13","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1038\/nature12147","volume":"498","author":"SR Floyd","year":"2013","unstructured":"Floyd SR, Pacold ME, Huang Q, Clarke SM, Lam FC, Cannell IG, et al. The bromodomain protein Brd4 insulates chromatin from DNA damage signalling. Nature. 2013;498:246\u201350.","journal-title":"Nature"},{"key":"570_CR14","doi-asserted-by":"publisher","first-page":"2935","DOI":"10.1021\/acs.nanolett.9b00021","volume":"19","author":"H Wang","year":"2019","unstructured":"Wang H, Tang Y, Fang Y, Zhang M, Wang H, He Z, et al. Reprogramming tumor immune microenvironment (TIME) and metabolism via biomimetic targeting codelivery of Shikonin\/JQ1. Nano Lett. 2019;19:2935\u201344.","journal-title":"Nano Lett"},{"key":"570_CR15","doi-asserted-by":"publisher","first-page":"2829","DOI":"10.1016\/j.celrep.2016.08.032","volume":"16","author":"H Zhu","year":"2016","unstructured":"Zhu H, Bengsch F, Svoronos N, Rutkowski MR, Bitler BG, Allegrezza MJ, et al. BET bromodomain inhibition promotes anti-tumor immunity by suppressing PD-L1 expression. Cell Rep. 2016;16:2829\u201337.","journal-title":"Cell Rep"},{"key":"570_CR16","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1146\/annurev-immunol-032712-100008","volume":"31","author":"G Kroemer","year":"2013","unstructured":"Kroemer G, Galluzzi L, Kepp O, Zitvogel L. Immunogenic cell death in cancer therapy. Annu Rev Immunol. 2013;31:51\u201372.","journal-title":"Annu Rev Immunol"},{"key":"570_CR17","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1016\/S0960-9822(00)00610-2","volume":"10","author":"TT Paull","year":"2000","unstructured":"Paull TT, Rogakou EP, Yamazaki V, Kirchgessner CU, Gellert M, Bonner WM. A critical role for histone H2AX in recruitment of repair factors to nuclear foci after DNA damage. Curr Biol. 2000;10:886\u201395.","journal-title":"Curr Biol"},{"key":"570_CR18","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.jconrel.2015.05.284","volume":"210","author":"E Moles","year":"2015","unstructured":"Moles E, Urban P, Jimenez-Diaz MB, Viera-Morilla S, Angulo-Barturen I, Busquets MA, et al. Immunoliposome-mediated drug delivery to plasmodium-infected and non-infected red blood cells as a dual therapeutic\/prophylactic antimalarial strategy. J Control Release. 2015;210:217\u201329.","journal-title":"J Control Release"},{"key":"570_CR19","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1126\/science.aaa3828","volume":"348","author":"BM Carreno","year":"2015","unstructured":"Carreno BM, Magrini V, Becker-Hapak M, Kaabinejadian S, Hundal J, Petti AA, et al. Cancer immunotherapy. A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells. Science. 2015;348:803\u20138.","journal-title":"Science"},{"key":"570_CR20","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.3389\/fimmu.2017.01594","volume":"8","author":"KM Hargadon","year":"2017","unstructured":"Hargadon KM. Strategies to improve the efficacy of dendritic cell-based immunotherapy for melanoma. Front Immunol. 2017;8:1594.","journal-title":"Front Immunol"},{"key":"570_CR21","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1146\/annurev.immunol.18.1.767","volume":"18","author":"J Banchereau","year":"2000","unstructured":"Banchereau J, Briere F, Caux C, Davoust J, Lebecque S, Liu YJ, et al. Immunobiology of dendritic cells. Annu Rev Immunol. 2000;18:767\u2013811.","journal-title":"Annu Rev Immunol"},{"key":"570_CR22","doi-asserted-by":"publisher","first-page":"1802134","DOI":"10.1002\/advs.201802134","volume":"6","author":"Q Chen","year":"2019","unstructured":"Chen Q, Liu L, Lu Y, Chen X, Zhang Y, Zhou W, et al. Tumor microenvironment-triggered aggregated magnetic nanoparticles for reinforced image-guided immunogenic chemotherapy. Adv Sci. 2019;6:1802134.","journal-title":"Adv Sci"},{"key":"570_CR23","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1038\/s41423-018-0026-y","volume":"16","author":"G Yu","year":"2019","unstructured":"Yu G, Wu Y, Wang W, Xu J, Lv X, Cao X, et al. Low-dose decitabine enhances the effect of PD-1 blockade in colorectal cancer with microsatellite stability by re-modulating the tumor microenvironment. Cell Mol Immunol. 2019;16:401\u20139.","journal-title":"Cell Mol Immunol"},{"key":"570_CR24","doi-asserted-by":"publisher","first-page":"120187","DOI":"10.1016\/j.biomaterials.2020.120187","volume":"255","author":"B Chen","year":"2020","unstructured":"Chen B, Gao A, Tu B, Wang Y, Yu X, Wang Y, et al. Metabolic modulation via mTOR pathway and anti-angiogenesis remodels tumor microenvironment using PD-L1-targeting codelivery. Biomaterials. 2020;255:120187.","journal-title":"Biomaterials"},{"key":"570_CR25","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s40425-018-0476-x","volume":"7","author":"C Maletzki","year":"2019","unstructured":"Maletzki C, Wiegele L, Nassar I, Stenzel J, Junghanss C. Chemo-immunotherapy improves long-term survival in a preclinical model of MMR-D-related cancer. J Immunother Cancer. 2019;7:8.","journal-title":"J Immunother Cancer"},{"key":"570_CR26","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1182\/blood.V97.1.192","volume":"97","author":"SE Street","year":"2001","unstructured":"Street SE, Cretney E, Smyth MJ. Perforin and interferon-gamma activities independently control tumor initiation, growth, and metastasis. Blood. 2001;97:192\u20137.","journal-title":"Blood"},{"key":"570_CR27","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1034\/j.1600-065X.2001.1820102.x","volume":"182","author":"S Sakaguchi","year":"2001","unstructured":"Sakaguchi S, Sakaguchi N, Shimizu J, Yamazaki S, Sakihama T, Itoh M, et al. Immunologic tolerance maintained by CD25+CD4+ regulatory T cells: their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance. Immunol Rev. 2001;182:18\u201332.","journal-title":"Immunol Rev"},{"key":"570_CR28","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/nrc1252","volume":"4","author":"G Dranoff","year":"2004","unstructured":"Dranoff G. Cytokines in cancer pathogenesis and cancer therapy. Nat Rev Cancer. 2004;4:11\u201322.","journal-title":"Nat Rev Cancer"},{"key":"570_CR29","doi-asserted-by":"publisher","first-page":"2895","DOI":"10.1002\/ijc.28060","volume":"133","author":"IC Lee","year":"2013","unstructured":"Lee IC, Huang YH, Chau GY, Huo TI, Su CW, Wu JC, et al. Serum interferon gamma level predicts recurrence in hepatocellular carcinoma patients after curative treatments. Int J Cancer. 2013;133:2895\u2013902.","journal-title":"Int J Cancer"},{"key":"570_CR30","doi-asserted-by":"crossref","first-page":"2977","DOI":"10.4049\/jimmunol.139.9.2977","volume":"139","author":"TJ Brown","year":"1987","unstructured":"Brown TJ, Lioubin MN, Marquardt H. Purification and characterization of cytostatic lymphokines produced by activated human T lymphocytes. Synergistic antiproliferative activity of transforming growth factor beta 1, interferon-gamma, and oncostatin M for human melanoma cells. J Immunol. 1987;139:2977\u201383.","journal-title":"J Immunol"},{"key":"570_CR31","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1038\/cr.2016.151","volume":"27","author":"A Tanaka","year":"2017","unstructured":"Tanaka A, Sakaguchi S. Regulatory T cells in cancer immunotherapy. Cell Res. 2017;27:109\u201318.","journal-title":"Cell Res"},{"key":"570_CR32","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-51537-7","volume":"9","author":"Y Gilad","year":"2019","unstructured":"Gilad Y, Eliaz Y, Yu Y, Han SJ, O\u2019Malley BW, Lonard DM. Drug-induced PD-L1 expression and cell stress response in breast cancer cells can be balanced by drug combination. Sci Rep. 2019;9:15099.","journal-title":"Sci Rep"}],"container-title":["Acta Pharmacologica Sinica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41401-020-00570-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41401-020-00570-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41401-020-00570-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,15]],"date-time":"2023-10-15T01:24:19Z","timestamp":1697333059000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41401-020-00570-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,11]]},"references-count":32,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["570"],"URL":"https:\/\/doi.org\/10.1038\/s41401-020-00570-8","relation":{},"ISSN":["1671-4083","1745-7254"],"issn-type":[{"value":"1671-4083","type":"print"},{"value":"1745-7254","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12,11]]},"assertion":[{"value":"14 September 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 November 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 December 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}